U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354919) titled 'Axelopran in Advanced Cancers' on Jan. 19.
Brief Summary: The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main questions it aims to answer are:
* Does axelopran show a signal for efficacy in slowing tumor progression?
* Is axelopran safe and tolerable for long-term use in this patient population?
* Does axelopran show a signal for efficacy in improving bowel function and quality of life?
*...